These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31562355)

  • 1. Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment.
    Chen TB; Lee YJ; Lin SY; Chen JP; Hu CJ; Wang PN; Cheng IH
    Sci Rep; 2019 Sep; 9(1):13984. PubMed ID: 31562355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment.
    Okonkwo OC; Mielke MM; Griffith HR; Moghekar AR; O'Brien RJ; Shaw LM; Trojanowski JQ; Albert MS;
    Arch Neurol; 2011 Jan; 68(1):113-9. PubMed ID: 21220682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study.
    Albani D; Marizzoni M; Ferrari C; Fusco F; Boeri L; Raimondi I; Jovicich J; Babiloni C; Soricelli A; Lizio R; Galluzzi S; Cavaliere L; Didic M; Schönknecht P; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Bocchio L; Salvatore M; Rossini PM; Tsolaki M; Visser PJ; Richardson JC; Wiltfang J; Bordet R; Blin O; Forloni G; Frisoni GB;
    J Alzheimers Dis; 2019; 69(1):37-48. PubMed ID: 30149449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.
    Mielke MM; Hagen CE; Wennberg AMV; Airey DC; Savica R; Knopman DS; Machulda MM; Roberts RO; Jack CR; Petersen RC; Dage JL
    JAMA Neurol; 2017 Sep; 74(9):1073-1080. PubMed ID: 28692710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.
    Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Zetterberg H; Abramowicz M; Scheffler M; Assal F; Garibotto V; Blennow K; Frisoni GB
    Alzheimers Res Ther; 2024 May; 16(1):110. PubMed ID: 38755703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
    Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
    ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.
    Marizzoni M; Ferrari C; Macis A; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Pizzini F; Rossini PM; Salvatore M; Schönknecht P; Soricelli A; Del Percio C; Hensch T; Hegerl U; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
    J Alzheimers Dis; 2019; 69(1):49-58. PubMed ID: 30958351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project.
    Verberk IMW; Hendriksen HMA; van Harten AC; Wesselman LMP; Verfaillie SCJ; van den Bosch KA; Slot RER; Prins ND; Scheltens P; Teunissen CE; Van der Flier WM
    Neurobiol Aging; 2020 May; 89():99-107. PubMed ID: 32081465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Chen TB; Lai YH; Ke TL; Chen JP; Lee YJ; Lin SY; Lin PC; Wang PN; Cheng IH
    Dement Geriatr Cogn Disord; 2019; 48(3-4):180-195. PubMed ID: 31991443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
    Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
    J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
    Riemenschneider M; Lautenschlager N; Wagenpfeil S; Diehl J; Drzezga A; Kurz A
    Arch Neurol; 2002 Nov; 59(11):1729-34. PubMed ID: 12433260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Fully-Automated High-Throughput Plasma Biomarker Assays for Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subjects.
    Giuffrè GM; Quaranta D; Vita MG; Costantini EM; Citro S; Carrozza C; De Ninno G; Calabresi P; Marra C
    J Prev Alzheimers Dis; 2024; 11(4):1073-1078. PubMed ID: 39044519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
    Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
    J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease.
    Tzen KY; Yang SY; Chen TF; Cheng TW; Horng HE; Wen HP; Huang YY; Shiue CY; Chiu MJ
    ACS Chem Neurosci; 2014 Sep; 5(9):830-6. PubMed ID: 25054847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.